Clene claims its PhII MS trial, half its intended size, cleared the primary goal. But can the biotech afford PhIII?

Clene Nanomedicine said its gold nanocrystal-based drug candidate, which failed an ALS trial last year, was better than placebo in a mid-stage study of patients with multiple sclerosis. But there are some big caveats to flag here.